OncoSec Medical (FRA:ONMA) Institutional Ownership : 1.22% (As of Jun. 05, 2024)

View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, OncoSec Medical's institutional ownership is 1.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, OncoSec Medical's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, OncoSec Medical's Float Percentage Of Total Shares Outstanding is 87.20%.

OncoSec Medical Institutional Ownership Historical Data

The historical data trend for OncoSec Medical's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Institutional Ownership Chart

OncoSec Medical Historical Data

The historical data trend for OncoSec Medical can be seen below:

	2022-09-30	2022-10-31	2022-11-30	2022-12-31	2023-01-31	2023-02-28	2023-03-31	2023-04-30	2023-05-31	2023-06-30
Institutional Ownership	4.96	4.96	4.92	0.62	0.61	0.60	2.45	1.60	1.22	1.22

OncoSec Medical Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

OncoSec Medical (FRA:ONMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ONCSQ:USA

Address

24 North Main Street, Pennington, NJ, USA, 08534

Website

https://www.oncosec.com

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical (FRA:ONMA) Headlines

No Headlines